Suppr超能文献

去甲肾上腺素和血管加压素与去甲肾上腺素和肾上腺素治疗脓毒性休克成人患者的比较。

Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock.

机构信息

1 Rush University Medical Center, Chicago, IL, USA.

2 Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Ann Pharmacother. 2019 Sep;53(9):877-885. doi: 10.1177/1060028019843664. Epub 2019 Apr 8.

Abstract

The optimal adjuvant vasopressor to norepinephrine in septic shock remains controversial. To compare durations of shock-free survival between adjuvant vasopressin and epinephrine. A retrospective, single-center, matched cohort study of adults with septic shock refractory to norepinephrine was conducted. Patients receiving norepinephrine not at target mean arterial pressure (MAP; 65 mm Hg) were initiated on vasopressin or epinephrine to raise MAP to target. Vasopressin-exposed patients were matched to epinephrine-exposed patients using propensity scores. Mortality outcomes were examined using multivariable Poisson regression with robust variance estimation. Of 166 patients, 96 (entire cohort) were included in the propensity score-matched cohort. Shock-free survival durations in the first 7 days were similar between epinephrine- and vasopressin-exposed patients in the matched cohort (median = 13.2 hours, interquartile range [IQR] = 0-121.0, vs median = 41.3 hours, IQR = 0-125.9; = 0.51). Seven- and 28-day mortality rates were similar in the matched cohort (7-day: 47.9% vs 39.6%, = 0.35; 28-day: 56.3% vs 58.3%, = 0.84). Mortality rates were similar between epinephrine- and vasopressin-exposed patients in propensity score-matched regression models with and without adjustments at 7 (relative risk [RR] = 1.28, 95% CI = 0.92-1.79; RR = 1.21, 95% CI = 0.81-1.81) and 28 days (RR = 1.04, 95% CI = 0.81-1.34; RR = 0.96, 95% CI = 0.69-1.34). Shock-free survival durations were similar in matched epinephrine- and vasopressin-exposed groups. Adjuvant epinephrine or vasopressin alongside norepinephrine to raise MAP to target requires further investigation.

摘要

在感染性休克中,去甲肾上腺素的最佳辅助升压药仍存在争议。比较辅助性血管加压素与肾上腺素在休克无生存时间上的差异。采用回顾性、单中心、匹配队列研究方法,对接受去甲肾上腺素治疗但未达到目标平均动脉压(65mmHg)的感染性休克患者进行研究。给予去甲肾上腺素但未达到目标平均动脉压的患者使用血管加压素或肾上腺素升高 MAP 以达到目标。使用倾向评分匹配血管加压素暴露患者和肾上腺素暴露患者。使用多变量泊松回归和稳健方差估计检查死亡率结果。在 166 例患者中,96 例(整个队列)纳入倾向评分匹配队列。在匹配队列中,肾上腺素组和血管加压素组患者在第 1 天至第 7 天的休克无生存时间相似(中位数=13.2 小时,四分位距[IQR]=0-121.0,vs 中位数=41.3 小时,IQR=0-125.9;=0.51)。在匹配队列中,第 7 天和第 28 天的死亡率相似(7 天:47.9%vs 39.6%,=0.35;28 天:56.3%vs 58.3%,=0.84)。在未调整和调整后的倾向评分匹配回归模型中,肾上腺素组和血管加压素组患者的死亡率在第 7 天(相对风险[RR]=1.28,95%CI=0.92-1.79;RR=1.21,95%CI=0.81-1.81)和第 28 天(RR=1.04,95%CI=0.81-1.34;RR=0.96,95%CI=0.69-1.34)时相似。在匹配的肾上腺素组和血管加压素组中,休克无生存时间相似。在去甲肾上腺素基础上加用肾上腺素或血管加压素以升高 MAP 至目标值需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验